Zejula Gets Priority Review for Late Stage Ovarian Cancer Indication
The sNDA is supported by data from the multicenter phase 2 QUADRA trial that evaluated the safety and activity of Zejula in 463 patients.
Gynecologic, Ovarian, and Cervical Cancer News
GYNECOLOGIC CANCER ADVISOR
Higher Surgical Volume May Improve Outcomes in Cervical Cancer
Surgery at high-volume centers is associated with decreased local recurrence risk and improved survival for women with early-stage cervical cancer.
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
Mirvetuximab soravtansine is the first folate receptor alpha-targeting antibody-drug conjugate.
Experts Recommend Cytologic Test Every 3 Years, High-Risk HPV Test Every 5 Years
A new study challenges the recommended use of cotesting for cervical cancer screening.
Intraperitoneal Chemotherapy Fails to Improve Outcomes in Advanced Ovarian Carcinoma
When paired with bevacizumab, neither intraperitoneal delivery of carboplatin nor cisplatin improved outcomes for patients with advanced ovarian carcinoma compared with intravenous delivery.
CDC: Recent Decline Seen in High-Grade Cervical Lesions
The number of cervical precancers (CIN2+ cases) in the United States declined from 2008 to 2016.
Late-Line Niraparib in Advanced Ovarian Cancer: A Continuum of Clinical Benefit in Subgroups Characterized by Clinical and Molecular Biomarkers
More accurate biomarkers are needed to better define subgroups of patients with ovarian cancer who are most likely to benefit from late-line niraparib.
Genetic Testing Underused in Breast, Ovarian Cancer
Pathogenic variants ID’d in 7.8 percent of patients with breast cancer, 14.5 percent with ovarian cancer
Chemoimmunotherapy Confers Survival Benefit in Patients With HPV16-Induced Cervical Cancer
Coadministration of the HPV16-specific vaccine, ISA101, with chemotherapy was found to be associated with stronger tumor immunity.
Dendritic Cell Vaccination in Ovarian Cancer May Induce Long-Lasting Antitumor Immunity
Median OS was significantly improved when dendritic cell vaccination therapy was added to standard second-line chemo in platinum-sensitive, relapsed ovarian cancer.
Improved Quality of Life After Concurrent Surgery for Endometrial Cancer and Incontinence
Concurrent surgery for cancer and stress urinary incontinence was associated with significantly improved QoL for women with early endometrial neoplasms and urinary stress incontinence.
TSR-042, a PD-1 Inhibitor, for Recurrent or Advanced Endometrial Cancer
According to researchers, responses to TSR-042 were seen in subgroups of patients with disease characterized as microsatellite instability (MSI)-high and MSI-low.
Atezolizumab Plus Bevacizumab in Advanced Cervical Cancer
Median PFS was only 2.9 months for women with advanced cervical cancer receiving the combination of atezolizumab plus bevacizumab.
Pembrolizumab Plus Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
A clinical benefit rate of 86% was observed in a phase 2 trial of pembrolizumab plus chemotherapy in patients with recurrent, platinum-resistant ovarian cancer.
Promising Early Results for Tisotumab Vedotin in Advanced Cervical Cancer
According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.
Racial Differences in Immune Escape Mechanisms of Ovarian Cancer
High expression of indoleamine 2.3-dioxygenase pathway genes correlated with the presence of immune escape mechanisms in ovarian cancers, according to researchers.
Early Evidence of Neratinib Benefit in HER2-Positive Metastatic Cervical Cancer
Single-agent neratinib was associated with durable responses in a subcohort of women in the SUMMIT trial.
Vitiligo May Be Associated With Reduced Risk of Internal Cancer
Reductions in the risk of cancer were more pronounced in men and younger patients with vitiligo.
Carboplatin Desensitization Associated With Improved Overall Survival in Recurrent Ovarian Cancer
The OS benefit of carboplatin desensitization was limited to the subgroup of women with recurrent ovarian cancer without deleterious germline BRCA1/2 mutations.
Maintenance Olaparib May Be More Cost-Effective Than Bevacizumab in BRCA-Mutant Ovarian Cancer
Researchers estimated cost effectiveness for first-line maintenance therapy with bevacizumab or olaparib in women with BRCA-mutant ovarian cancer.
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
